Abstract: A high-voltage optical transformer may include (1) an array of light-emitting devices that are connected in parallel with one another and are electrically coupled to an electrical input, (2) a transfer medium, and (3) an array of photovoltaic cells that (A) are optically coupled to the array of light-emitting devices via the transfer medium, (B) are connected in series with one another, and (C) produce an electrical output whose voltage is higher than the electrical input. Various other apparatuses, systems, and methods are also disclosed.

Abstract: The present invention relates to a new process for the production of specific intermediates, which are preferably used in the production of vitamin A, vitamin A acetate, or ?-carotene and derivatives thereof, e.g. canthaxanthin, astaxanthin or zeaxanthin.

Abstract: Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.

Abstract: CRISPR-based gene-drive system for inhibiting antibiotic resistance of bacteria, including Escherichia coli that efficiently copies a gRNA cassette and adjacent cargo that are flanked with sequences homologous to the targeted gRNA/Cas9 cleavage site. This “pro-active” genetic system (Pro-AG) functionally inactivates an antibiotic resistance marker on a high copy number plasmid with greater efficiency than control CRISPR-based methods. Pro-AG can effectively edit large plasmids or single-copy genomic targets, or introduce functional genes, with numerous applications to biotechnology and biomedicine.

Abstract: This method includes emitting, by an emitter at an emitting depth, moved along an axis, at least one incident sound wave at an emitting frequency, receiving a first sound wave reflected by a first reflective object at a first depth and a second sound wave reflected by a second reflective object at a second depth, greater than the first depth, providing a first velocity at the first depth, and determining a second velocity of the sound waves at the second depth, from the frequencies of the first and second reflected sound waves, the emitting frequency and the first velocity.

Abstract: This method includes emitting, by an emitter at an emitting depth, moved along an axis, at least one incident sound wave at an emitting frequency, receiving a first sound wave reflected by a first reflective object at a first depth and a second sound wave reflected by a second reflective object at a second depth, greater than the first depth, providing a first velocity at the first depth, and determining a second velocity of the sound waves at the second depth, from the frequencies of the first and second reflected sound waves, the emitting frequency and the first velocity.

Abstract: A pharmaceutical formulation is described comprising a therapeutically effective amount of an antibody, an acetate buffer, a lyoprotectant, a bulking agent and a surfactant.

Abstract: A pharmaceutical formulation is described comprising a therapeutically effective amount of an antibody, an acetate buffer, a lyoprotectant, a bulking agent and a surfactant.